Proactive Investors - Run By Investors For Investors

Imugene Limited on road to raising

Imugene Limited on road to raising

Clinical stage immuno-oncology company Imugene Limited (ASX:IMU) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Imugene is currently preparing to release capital raising details.

The company is developing HER-2+ gastric and breast cancer immunotherapies.

The halt will remain in place until the opening of trade on Wednesday 9th September 2015, or earlier if an announcement is made to the market.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use